Fig. 8.

Transgenic expression of APP and TTBK1 induces physical association of CRMP2 and tau in vivo. a EC and hippocampus lysates were immunoprecipitated with anti-pT514-CRMP2 antibody, followed by immunoblotting of the immunoprecipitated samples with AT8 (anti-pS202/pS205 pTau) or Tau46 (total tau). Five % of input lysate was also blotted for AT8 and total tau (Tau46). b Quantification of AT8 or Tau46-immureactive bands after normalization with co-precipitated pT514 CRMP2level from EC (left panel) or hippocampal tissues (Hp, right panel). B. Signal intensity was quantified. The error bars indicate SEM. * and ** denote p < 0.05, or 0.01 as determined by one-way ANOVA and Tukey post hoc (N = 6 per sample). ANOVA: EC for AT8; F (3, 20) = 324.13 (p < 0.0001), EC for Tau46; F (3, 20) = 231.65 (p < 0.0001), Hp for AT8; F (3,20) = 389.56 (p < 0.0001), Hp for Tau46; F (3, 20) = 265.2 (p < 0.0001)